| Autor: |
Mathias Martins, Gabriela M. Do Nascimento, Antonella Conforti, Jessica C.G. Noll, Joseph A. Impellizeri, Elisa Sanchez, Bettina Wagner, Lucia Lione, Erika Salvatori, Eleonora Pinto, Mirco Compagnone, Brian Viscount, James Hayward, Clay Shorrock, Luigi Aurisicchio, Diego G. Diel |
| Rok vydání: |
2022 |
| Předmět: |
|
| DOI: |
10.1101/2022.09.29.510112 |
| Popis: |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has caused more than 600 million cases and over 6 million deaths worldwide. Vaccination has been the main strategy used to contain the spread of the virus, and to avoid hospitalizations and deaths. Currently, there are two mRNA-based and one adenovirus vectored vaccines approved and available for use in the U.S. population. The versatility, low cost and rapid-to-manufacture attributes of DNA vaccines are important advantages over other platforms. However, DNA vaccination must meet higher efficiency levels for use in humans. Importantly, in vivo DNA delivery combined with electroporation (EP) has been successfully used in the veterinary field. Here we evaluated the safety, immunogenicity and protective efficacy of a novel linear SARS-CoV-2 DNA vaccine candidate for delivered by intramuscular injection followed by electroporation (Vet-ePorator™) in ferrets. The results demonstrated that the linear SARS-CoV-2 DNA vaccine candidate did not cause unexpected side effects, and was able to elicit neutralizing antibodies and T cell responses using a low dose of the linear DNA construct in prime-boost regimen, and significantly reduced shedding of infectious SARS-CoV-2 through oral and nasal secretions in a ferret model. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
